Related Experiment Video
Updated: Jul 17, 2025
An Immunological Model for Heterotopic Heart and Cardiac Muscle Cell Transplantation in Rats
Published on: May 8, 2020
Feasibility of Interleukin-6 Receptor Blockade in Cardiac Antibody-mediated Rejection
April A Pottebaum1, Spenser E January1, Chang Liu2
1Department of Pharmacy, Barnes Jewish Hospital, St. Louis, MO.
Background:
Antibody-mediated rejection (AMR) remains a significant cause of heart transplant mortality with few effective therapies.
Methods:
This study aimed to describe initial experience of using interleukin-6 receptor blockade with tocilizumab in the treatment of acute cardiac AMR at Barnes-Jewish Hospital/Washington University Transplant Center from July 2017 to May 2021 (n = 7). Clinical, echocardiographic, and serum alloantibody data were analyzed before and after treatment.
Results:
All participants demonstrated marked improvement in functional status. Echocardiographic data following 4-6 mo of tocilizumab revealed significant improvements in biventricular systolic function for all participants. Consistent reductions in donor-specific HLA or angiotensin type I receptor antibodies were not observed, suggesting that tocilizumab may act downstream of antibody production. No patient experienced drug-related complications that necessitated discontinuation of therapy.
Conclusions:
These findings provide initial insights into the safety and efficacy of interleukin-6 receptor blockade in the treatment of cardiac AMR and support the design of larger prospective studies.
